Gain Therapeutics, Inc. (GANX) stock
GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.24 (+25.51%)
Close on Nov 17, 2026Market cap $51.50MP/E –Yield –
Gain Therapeutics cash
Cash and short-term investments held at the end of each period.
Gain Therapeutics's cash was $13.08M at Jun 30, 2026. For fiscal 2025 it was $20.84M, up 100.0% from the year before. The highest annual figure on record is $36.91M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.84M | +100.0% |
| FY2024 | Dec 31, 2024 | $10.42M | -38.0% |
| FY2023 | Dec 31, 2023 | $16.80M | -16.7% |
| FY2022 | Dec 31, 2022 | $20.17M | -45.4% |
| FY2021 | Dec 31, 2021 | $36.91M | +391.9% |
| FY2020 | Dec 31, 2020 | $7.50M | +2292.2% |
| FY2019 | Dec 31, 2019 | $313.70K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.08M | +94.4% |
| Q1 FY2026 | Mar 31, 2026 | $16.54M | +81.7% |
| Q4 FY2025 | Dec 31, 2025 | $20.84M | +100.0% |
| Q3 FY2025 | Sep 30, 2025 | $8.81M | -27.1% |
| Q2 FY2025 | Jun 30, 2025 | $6.73M | -60.3% |
| Q1 FY2025 | Mar 31, 2025 | $9.10M | -28.3% |
| Q4 FY2024 | Dec 31, 2024 | $10.42M | -38.0% |
| Q3 FY2024 | Sep 30, 2024 | $12.08M | -1.8% |
| Q2 FY2024 | Jun 30, 2024 | $16.97M | +4.6% |
| Q1 FY2024 | Mar 31, 2024 | $12.70M | -28.8% |
| Q4 FY2023 | Dec 31, 2023 | $16.80M | -16.7% |
| Q3 FY2023 | Sep 30, 2023 | $12.30M | -46.0% |
| Q2 FY2023 | Jun 30, 2023 | $16.22M | -33.2% |
| Q1 FY2023 | Mar 31, 2023 | $17.85M | -48.1% |
| Q4 FY2022 | Dec 31, 2022 | $20.17M | -45.4% |
| Q3 FY2022 | Sep 30, 2022 | $22.76M | -44.5% |
| Q2 FY2022 | Jun 30, 2022 | $24.28M | -43.8% |
| Q1 FY2022 | Mar 31, 2022 | $34.37M | -26.3% |
| Q4 FY2021 | Dec 31, 2021 | $36.91M | +391.9% |
| Q3 FY2021 | Sep 30, 2021 | $41.01M | +342.0% |
| Q2 FY2021 | Jun 30, 2021 | $43.20M | +8312.1% |
| Q1 FY2021 | Mar 31, 2021 | $46.64M | +4834.5% |
| Q4 FY2020 | Dec 31, 2020 | $7.50M | +2292.2% |
| Q3 FY2020 | Sep 30, 2020 | $9.28M | – |
| Q2 FY2020 | Jun 30, 2020 | $513.60K | – |
| Q1 FY2020 | Mar 31, 2020 | $945.11K | – |
| Q4 FY2019 | Dec 31, 2019 | $313.70K | – |
See a number that looks wrong?